Sugi Predict

Sugi Predict / Compounds / SCHEMBL1961694

SCHEMBL1961694

SCHEMBL1961694

COC(=O)C1(CN)CCN(Cc2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ CYP2D6 P10635 7/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ OPRM1 P35372 1/20 0.48
▸ OPRD1 P41143 1/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ KCNH2 Q12809 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20608072 0.89 LMNA (0.64) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL19779408 0.88 KMT2A (0.53) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL2470923 0.87 CYP2D6 (0.54) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL15367649 0.86 KMT2A (0.53) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL14517088 0.86 CYP2D6 (0.50) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL12691063 0.85 CYP2D6 (0.53) CYP2D6ALDH1A1CYP3A4TSHR
SCHEMBL2468808 0.85 CYP2D6 (0.49) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL21287577 0.83 KMT2A (0.57) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL18203100 0.83 L3MBTL1 (0.63) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1
SCHEMBL2470540 0.82 CYP2D6 (0.47) KMT2AMEN1L3MBTL1CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4067355-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS Mission Therapeutics Limited (GB) 2022-10-05 — — EP disclosed
EP-3423454-B1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-05-25 — — EP disclosed
US-20220106315-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-04-07 — — US disclosed
CN-108602823-B Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors 特殊治疗有限公司 2022-04-01 — — CN disclosed
US-11236092-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-02-01 — — US disclosed
US-20200247803-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-08-06 — — US disclosed
US-10654853-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-05-19 — — US disclosed
US-20190048008-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-02-14 — — US disclosed
EP-3423454-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS Mission Therapeutics Limited (GB) 2019-01-09 — — EP disclosed
US-20160159800-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2016-06-09 — — US disclosed
US-20140288109-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2014-09-25 — — US disclosed
US-20140288109-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2014-09-25 — — US disclosed
US-8772286-B2 MK2 inhibitors MERCK SHARP & DOHME B.V. (NL) 2014-07-08 — — US disclosed
US-8772286-B2 MK2 inhibitors MERCK SHARP & DOHME B.V. (NL) 2014-07-08 — — US disclosed
EP-2513111-B1 MK2 INHIBITORS MERCK SHARP & DOHME (NL) 2013-10-02 — — EP disclosed
EP-2513111-A1 MK2 INHIBITORS MSD Oss B.V. (NL) 2012-10-24 — — EP disclosed
US-20120245175-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2012-09-27 — — US disclosed
US-20120245175-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2012-09-27 — — US disclosed
WO-2011073119-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2011-06-23 — — WO disclosed
WO-2011073119-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288109-A1 MK2 INHIBITORS MKNK2, MAPKAPK2, MAP3K2 KMT2A 140/4885MEN1 359/4885L3MBTL1 4555/4885
US-20220106315-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 KMT2A 1025/4885MEN1 4242/4885L3MBTL1 3004/4885
US-20200247803-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 KMT2A 1025/4885MEN1 4242/4885L3MBTL1 3004/4885
US-20160159800-A1 MK2 INHIBITORS MKNK2, MAPKAPK2, MAP3K2 KMT2A 152/4885MEN1 336/4885L3MBTL1 4532/4885
US-10654853-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors OTUB1, UBE2E1, RCE1 KMT2A 1025/4885MEN1 4242/4885L3MBTL1 3004/4885
US-20190048008-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 KMT2A 1025/4885MEN1 4242/4885L3MBTL1 3004/4885
US-11236092-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors OTUB1, UBE2E1, RCE1 KMT2A 1025/4885MEN1 4242/4885L3MBTL1 3004/4885
US-20120245175-A1 MK2 INHIBITORS MKNK2, MAPKAPK2, MAP3K2 KMT2A 140/4885MEN1 359/4885L3MBTL1 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.